Focus: Parexel is a large global Contract Research Organization (CRO) headquartered in Boston with 10,001-50,000 employees, providing end-to-end clinical trial services, regulatory affairs support, and trial management across multiple therapeutic areas.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Growing — net +13 jobs in 30d
209 jobs added vs 196 removed. Steady team buildout.
Parexel is a stable, large-scale CRO ideal for building clinical operations and regulatory expertise, but offers less direct pharmaceutical innovation exposure than biotech or pharma companies.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Parexel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Parexel's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Teladoc Health, Inc. (TDOC) (CIK 0001477449) — EX-99.1
EX-99.1
8-K Filing: Cryoport, Inc. (CYRX) (CIK 0001124524) — EXHIBIT 99.1
EXHIBIT 99.1
Clinical Trial Supplies Company Evaluation Report 2025: Market Led by Thermo Fisher Scientific, Sharp Services, and Parexel Through End-to-End Capabilities Span Packaging, Logistics, Trial Management - ResearchAndMarkets.com - Business Wire
Clinical Trial Supplies Company Evaluation Report 2025: Market Led by Thermo Fisher Scientific, Sharp Services, and Parexel Through End-to-End Capabilities Span Packaging, Logistics, Trial Management - ResearchAndMarkets.com Business Wire
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies.
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo